What is Biotest AG (BTTAY)?

Biotest AG (BTTAY) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of BTTAY?

The current price of BTTAY is $24.21. Prices are updated in real time on Stocks360.

What is BTTAY's price-to-earnings (PE) ratio?

BTTAY's trailing twelve-month PE ratio is 61.10, based on current price and earnings per share data available on Stocks360.

What is BTTAY's market capitalization?

BTTAY's market capitalization is $942,115,165.00, placing it in the small-cap tier.

Does BTTAY pay a dividend?

Yes. BTTAY has a trailing twelve-month dividend yield of 1.03%. Dividend data is sourced from financial market providers and displayed on Stocks360.

Biotest AG (BTTAY)

Stock analysis · OTC · Healthcare · Biotechnology

$24.21

Market Cap

$942.12M

PE (TTM)

61.10

EPS (TTM)

N/A

Dividend Yield

1.03%

Beta

0.00

Day Range

$24.21 – $24.21

52-wk Range

$22.80 – $24.27

Avg Volume

N/A

Volume

0.00

Biotest AG (BTTAY) is a publicly traded company in the Healthcare sector. Latest price: $24.21. Market cap $942.12M. Trailing PE 61.10. Dividend yield 1.03%. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Proprietary Signals

Signal snapshot temporarily unavailable.

About Biotest AG

Operating globally from its headquarters in Dreieich, Germany, Biotest AG is a pharmaceutical company established in 1946. It specializes in the research, development, manufacturing, and commercialization of biological medicines. The company's operations are structured across its Therapy, Plasma & Services, and Other divisions. Biotest's product portfolio addresses critical needs within hematology, clinical immunology, and intensive care medicine. For instance, Biotest provides treatments for hemophilia, including Haemoctin and Vihuma for hemophilia A, and Haemonine for hemophilia B, addressing both acute episodes and long-term prevention. Its infectious disease portfolio features therapies like Cytotect CP for cytomegalovirus, Varitect for varicella zoster virus, and several Hepatitis B-related products such as Fovepta (for neonate prophylaxis), Hepatect (reinfection prophylaxis), and Zutectra (post-liver transplant reinfection prevention). For immune system disorders and certain neurological conditions, Biotest offers Intratect and IgG Next Generation, targeting primary and secondary antibody deficiencies, and autoimmune diseases. Additionally, Biotest produces Albiomin and Bise…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	61.10×
P/S (TTM)	1.16×
P/B	3.04×
P/FCF (TTM)	26.22×
EV / EBITDA	11.08×
EV / Sales	1.84×
Earnings Yield	1.64%
Free Cash Flow Yield	3.81%
Dividend Yield	102.88%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$1.33B
Revenue (TTM)	$726.20M
Net Income (TTM)	$13.81M
Free Cash Flow (TTM)	$51.66M
Net Debt	$489.40M
Working Capital	$649.40M
Gross Margin	30.82%
Operating Margin	13.01%
Net Margin	3.64%
Return on Equity	5.13%
Return on Invested Capital	4.18%